Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX3397 (Pexidartinib) in KIT-mutated melanoma
NCT02975700Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pexidartinib in melanoma, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Best Overall Response at 18 months and Objective Response Rate at 18 months. Started Jan 2017; status: completed.
02
Drugs
pexidartinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02975700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975700.